RAS mutational status (at time of diagnosis)BRAF mutational status—V600E—(alongside assessment of RAS)MSI testing (in metastatic disease setting)DPD deficiency testing (option)UGT1A1 phenoyping (option). The gene discussed is UGT1A1; the disease is metastatic neoplasm.